$156.88
0[0.00%]
At close: Apr 26
$156.88
0[0.00%]
PreMarket: 4:20PM EDT
Krystal Biotech
(NASDAQ:KRYS)Latest News for Krystal Biotech Stock (NASDAQ:KRYS)
Krystal Biotech Stock (NASDAQ: KRYS)
Categories: All
Monday, April 22, 2024
- HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $200 Price TargetBenzinga Newsdesk - 6 days ago
- Krystal Biotech Has Dosed The First Patient In Its Phase 1 Clinical Trial (KYANITE-1) Evaluating Inhaled KB707 For Locally Advanced Or Metastatic Solid Tumors Of The LungBenzinga Newsdesk - 6 days ago
Wednesday, April 17, 2024
Tuesday, April 16, 2024
Wednesday, March 13, 2024
Tuesday, March 12, 2024
Tuesday, March 05, 2024
Thursday, February 29, 2024
Tuesday, February 27, 2024
- Krystal Biotech Analysts Increase Their Forecasts Following Q4 ResultsAvi Kapoor - Feb 27, 2024, 1:03PM
- Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $195Benzinga Newsdesk - Feb 27, 2024, 12:25PM
- Guggenheim Maintains Buy on Krystal Biotech, Raises Price Target to $175Benzinga Newsdesk - Feb 27, 2024, 12:16PM
Monday, February 26, 2024
- Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Feb 26, 2024, 1:57PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Feb 26, 2024, 12:31PM
- Krystal Biotech shares are trading higher after the company reported better-than-expected financial results.Luke J Jacobi - Feb 26, 2024, 8:29AM
- Krystal Biotech Q4 EPS $0.30 Beats $(0.39) Estimate, Sales $42.14M Beat $28.61M EstimateBenzinga Newsdesk - Feb 26, 2024, 8:12AM
- Krystal Biotech Expects FY24 Non-GAAP R&D And SG&A Expense Of $150M-$175MBenzinga Newsdesk - Feb 26, 2024, 8:03AM
- Krystal Biotech Reports Product Revenue, Net Of $50.7M For The Year Ended December 31, 2023Benzinga Newsdesk - Feb 26, 2024, 7:56AM
- Earnings Scheduled For February 26, 2024Benzinga Insights - Feb 26, 2024, 4:47AM
Friday, February 23, 2024
Tuesday, February 13, 2024
Thursday, February 08, 2024
Monday, January 29, 2024
Tuesday, January 16, 2024
Thursday, January 04, 2024
Tuesday, December 19, 2023
Wednesday, December 13, 2023
Monday, November 27, 2023
Monday, November 20, 2023
Tuesday, November 07, 2023
Monday, November 06, 2023
- Krystal Biotech shares are trading lower after the company reported Q3 financial results.Benzinga Newsdesk - Nov 6, 2023, 11:54AM
- Earnings Scheduled For November 6, 2023Benzinga Insights - Nov 6, 2023, 8:24AM
- Krystal Biotech Q3 EPS $2.79 Vs $(1.17) Estimate, Sales $8.56M Beat $6.32M EstimateBenzinga Newsdesk - Nov 6, 2023, 7:02AM
Friday, November 03, 2023
Tuesday, October 24, 2023
Thursday, October 12, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023Benzinga Insights - Oct 12, 2023, 11:00AM
- 5 Analysts Have This to Say About Krystal BiotechBenzinga Insights - Oct 12, 2023, 10:00AM
- Citigroup Initiates Coverage On Krystal Biotech with Buy Rating, Announces Price Target of $160Benzinga Newsdesk - Oct 12, 2023, 8:24AM
Thursday, September 21, 2023
Thursday, September 07, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023Benzinga Insights - Sep 7, 2023, 11:00AM
- 5 Analysts Have This to Say About Krystal BiotechBenzinga Insights - Sep 7, 2023, 8:00AM
- Berenberg Initiates Coverage On Krystal Biotech with Buy Rating, Announces Price Target of $154Benzinga Newsdesk - Sep 7, 2023, 5:52AM
Tuesday, September 05, 2023
Monday, August 21, 2023
- Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100MNabaparna Bhattacharya - Aug 21, 2023, 10:39AM
- Market-Moving News for August 21stBenzinga Newsdesk - Aug 21, 2023, 8:27AM
- Krystal Biotech shares are trading higher after the company sold its Rare Pediatric Disease Priority Review Voucher for $100M.Benzinga Newsdesk - Aug 21, 2023, 8:22AM
- Krystal Biotech Has Completed The Sale Of Its Rare Pediatric Disease Priority Review Voucher For $100MBenzinga Newsdesk - Aug 21, 2023, 7:15AM